Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.72 +0.30 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
43 44 Next >
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
AstraZeneca Healthcare Foundation Awards Seven US Nonprofits More Than $900k to Improve Heart Health and Advance Health Equity
From AstraZeneca HealthCare Foundation
Via Business Wire
Multiple Bits Of Bad News
Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser. 
Via Talk Markets
AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus... 
Via Benzinga
4 No-Brainer Pharmaceutical Stocks to Buy in October
While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical... 
Via Talk Markets
Exposures COVID-19
AstraZeneca, Sputnik Light COVID-19 Vaccine Mix Shows Strong Antibody Growth: Reuters
A small-scale study of AstraZeneca Plc (NASDAQ: AZN) COVID-19 combined with Sputnik Light vaccines has shown robust antibody growth in most of the study's... 
Via Benzinga
Exposures COVID-19
10 Biggest Price Target Changes For Monday
Morgan Stanley cut Amazon.com, Inc. (NASDAQ:AMZN)... 
Via Benzinga
AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
From AstraZeneca
Via Business Wire
Why AstraZeneca Stock Is Trading Higher Today
AstraZeneca (NASDAQ: AZN) shares are trading higher after the company announced lynparza PROpel trial met the primary endpoint in metastatic castration-resistant prostate... 
Via Benzinga
Sinovac's COVID-19 Vaccine Shows Efficacy, But Lags Rivals In Malaysian Study: Reuters
According to a real-world study from Malaysia, Sinovac Biotech Ltd's (NASDAQ: SVA) COVID-19 vaccine, CoronaVac, showed effectiveness against serious illness. ... 
Via Benzinga
Exposures COVID-19
AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients
AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate... 
Via Benzinga
LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
From AstraZeneca
Via Business Wire
China's Rescue Of Evergrand
The number of jobless last week was higher than the forecast, at 351,000 vs 320,000. The recovery is lagging. 
Via Talk Markets
RedHill Settles Movantik Patent Litigation With Aurobindo
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced a settlement and license agreement with Aurobindo Pharma USA Inc resolving their patent litigation in... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
AstraZeneca Invests In Imperial College's Self-Amplifying RNA Tech
AstraZeneca Plc (NASDAQ: AZN) struck a deal with a startup for a self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. Under the... 
Via Benzinga
Why Corvus Pharmaceuticals Stock Is Down Today
Profit taking appears to be in full effect today with this small-cap biotech. 
Via The Motley Fool
Exposures COVID-19
AstraZeneca To Inject $360M In Irish API Manufacturing Site
AstraZeneca plc (NASDAQ: AZN) will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs). The... 
Via Benzinga
Here's Why Everyone's Talking About AstraZeneca Right Now
The company's next-generation treatment for breast cancer could become the new standard of care. 
Via The Motley Fool
Exposures COVID-19
Why AstraZeneca and Surface Oncology Rose Today
The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi. 
Via The Motley Fool
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor... 
Via Benzinga
Pharma, Tech and Finance
Good news on some drugs was not enough to boost stock markets. 
Via Talk Markets
Why AstraZeneca Shares Are Trading Higher Today
AstraZeneca PLC (NASDAQ: AZN) is trading higher Monday after the company announced its Enhertu data that was presented at the European Society for Medical Oncology ... 
Via Benzinga
AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data
AstraZeneca plc (NASDAQ: AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies etoposide plus... 
Via Benzinga
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
Visualizing the World’s Biggest Pharmaceutical Companies
Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet
Toward the end of trading Friday, the Dow traded down 0.47% to 4,587.22 while the NASDAQ fell 1.05% to 15,023.11. The S&P also fell, dropping 0.85% to 4,435.65. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.